These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33765700)

  • 1. [Chinese experts suggestions on the application of esmolol injections in patients with arrhythmia].
    Arrhythmia Pharmacotherapy Group, Arrhythmia Branch of Chinese Society of Biomedical Engineering
    Zhonghua Nei Ke Za Zhi; 2021 Apr; 60(4):314-320. PubMed ID: 33765700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia.
    Sung RJ; Blanski L; Kirshenbaum J; MacCosbe P; Turlapaty P; Laddu AR
    J Clin Pharmacol; 1986 Mar; 26(S1):A15-A26. PubMed ID: 2870082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esmolol: a novel cardioselective, titratable, intravenous beta-blocker with ultrashort half-life.
    Covinsky JO
    Drug Intell Clin Pharm; 1987 Apr; 21(4):316-21. PubMed ID: 2882993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
    Barbier GH; Shettigar UR; Appunn DO
    Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esmolol in acute ischemic syndromes.
    Mitchell RG; Stoddard MF; Ben-Yehuda O; Aggarwal KB; Allenby KS; Trillo RA; Loyd R; Chang CT; Labovitz AJ
    Am Heart J; 2002 Nov; 144(5):E9. PubMed ID: 12422138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.
    Angaran DM; Schultz NJ; Tschida VH
    Clin Pharm; 1986 Apr; 5(4):288-303. PubMed ID: 2871961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias.
    Gray RJ; Bateman TM; Czer LS; Conklin CM; Matloff JM
    J Am Coll Cardiol; 1985 Jun; 5(6):1451-6. PubMed ID: 2860148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group.
    Anderson S; Blanski L; Byrd RC; Das G; Engler R; Laddu A; Lee R; Rajfer S; Schroeder J; Steck JD
    Am Heart J; 1986 Jan; 111(1):42-8. PubMed ID: 2868645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Esmolol in anesthesiology: pharmacology and indications].
    Fita G; Gomar C; Rovira I
    Rev Esp Anestesiol Reanim; 1999 Nov; 46(9):404-14. PubMed ID: 10613078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esmolol prevents and suppresses arrhythmias during halothane anaesthesia in dogs.
    Dimich I; Lingham R; Narang J; Sampson I; Shiang H
    Can J Anaesth; 1992 Jan; 39(1):83-6. PubMed ID: 1346371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esmolol in the treatment of severe arrhythmia after acute trichloroethylene poisoning.
    Mortiz F; de La Chapelle A; Bauer F; Leroy JP; Goullé JP; Bonmarchand G
    Intensive Care Med; 2000 Feb; 26(2):256. PubMed ID: 10784325
    [No Abstract]   [Full Text] [Related]  

  • 12. Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker.
    Gray RJ
    Chest; 1988 Feb; 93(2):398-403. PubMed ID: 2892647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of an ultrashort-acting beta-receptor blocker (esmolol) in patients with acute myocardial ischemia and relative contraindications to beta-blockade therapy.
    Kirshenbaum JM; Kloner RF; McGowan N; Antman EM
    J Am Coll Cardiol; 1988 Sep; 12(3):773-80. PubMed ID: 2900259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings.
    Turlapaty P; Laddu A; Murthy VS; Singh B; Lee R
    Am Heart J; 1987 Oct; 114(4 Pt 1):866-85. PubMed ID: 2889341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.
    Mooss AN; Hilleman DE; Mohiuddin SM; Hunter CB
    Ann Pharmacother; 1994 Jun; 28(6):701-3. PubMed ID: 7919552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esmolol: a short-acting titratable beta-blocker in acute myocardial ischemia.
    Viray R; Turlapaty P; Laddu A
    Int J Clin Pharmacol Ther Toxicol; 1988 Mar; 26(3):153-61. PubMed ID: 2900818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Esmolol as a bolus for prevention of sympathetic adrenergic reactions following induction of anesthesia].
    Schäffer J; Karg C; Piepenbrock S
    Anaesthesist; 1994 Nov; 43(11):723-9. PubMed ID: 7840400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the potassium channel blocker tedisamil with the beta-adrenoceptor blocker esmolol and the calcium antagonist gallopamil in patients with coronary artery disease.
    Mitrovic V; Oehm E; Thormann J; Pitschner H; Haberbosch W
    Clin Cardiol; 1998 Jul; 21(7):492-502. PubMed ID: 9669058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esmolol--a short-acting i.v. beta-blocker.
    Med Lett Drugs Ther; 1987 Jun; 29(742):57-8. PubMed ID: 2884558
    [No Abstract]   [Full Text] [Related]  

  • 20. In rabbits, landiolol, a new ultra-short-acting beta-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol.
    Sasao J; Tarver SD; Kindscher JD; Taneyama C; Benson KT; Goto H
    Can J Anaesth; 2001 Nov; 48(10):985-9. PubMed ID: 11698317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.